Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593248 | 0.64 | — | — | |
| SCHEMBL1592783 | 0.63 | — | — | |
| SCHEMBL2500830 | 0.61 | PNMT (0.30) | PNMT | |
| SCHEMBL3743138 | 0.57 | — | — | |
| SCHEMBL16603037 | 0.57 | — | — | |
| SCHEMBL21593110 | 0.57 | — | — | |
| SCHEMBL15888431 | 0.56 | PNMT (0.32) | PNMT | |
| SCHEMBL14838575 | 0.55 | — | — | |
| SCHEMBL952998 | 0.55 | — | — | |
| SCHEMBL237770 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3545956-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2020080960-A1 | COMPOUNDS FOR TREATING DIABETES AND/OR RELATED CONDITIONS | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-04-23 | — | — | WO | disclosed |
| EP-3044223-B1 | 2,3-DIHYDRO-1H-INDEN-1-ONE DERIVATIVES AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA) ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3545956-A1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | Arrien Pharmaceuticals LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2986300-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2931722-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | Arrien Pharmaeuticals LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014172513-A2 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014093383-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | VANKAYALAPATI HARIPRASAD | 2010-09-02 | — | — | US | disclosed |
| WO-2010098866-A1 | CYCLOPENTATHIOPHENE/CYCLOHEXATHIOPHENE DNA METHYLTRANSFERASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | DNMT3B, DNMT1, DNMT3L | PNMT 86/4885 |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | PNMT 4115/4885 |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | PNMT 4115/4885 |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | JAK3, TYK2, JAK2 | PNMT 4456/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | PNMT 4115/4885 |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | PNMT 4115/4885 |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | PNMT 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.